Abstract:BackgroundEpilepsy is one of the most common neurological disorders, affecting 1.1% adults in United States. Valproic acid (VPA) is an antiepileptic drug with narrow therapeutic window that requires close monitoring of the blood concentration. VPA is highly protein-bound, and the unbound free VPA (fVPA) is the bioactive form responsible for the pharmaceutical effects as well as the toxicity. However, fVPA is not commonly measured in most laboratories but is a test that needs to be sent out to reference laboratories, and the sendout test has a long turnaround time which delays timely patient care. The aim of the study was to develop fVPA estimating equations, to decrease the turnaround time and reduce adverse events, and ultimately improve patients' outcomes.MethodsWe retrospectively collected the laboratory results of total valproic acid (tVPA), fVPA and serum albumin along with the patients' demographic characteristics and other clinical data from 2013 to 2023 in our institution. While the albumin measurement was divided into normal (≥3.5 g/dl) and hypoalbuminemia (<3.5 g/dl) groups, the tVPA and fVPA were categorized into subtherapeutic, therapeutic, and supratherapeutic ranges. Using stepwise model selection, several linear regression equations were developed to predict fVPA concentration for total patients, patients with normal albumin only, and patients with hypoalbuminemia only. The estimated fVPA was then compared to the measured fVPA. The data were analyzed using SAS 9.4, SPSS 28.0 and EP Evaluator EE12.ResultsA total of 344 concurrent measurements of tVPA/fVPA/serum albumin from 157 patients were obtained, including 180 measurements from patients with normal albumin levels and 164 measurements from patients with hypoalbuminemia. In the patients with normal albumin levels, 32 (17%) were discordant between tVPA and fVPA. More than half of them had therapeutic tVPA but supratherapeutic fVPA. In contrast, 120 (73%) were discordant for the patients with hypoalbuminemia. About half of them had subtherapeutic tVPA but therapeutic fVPA. Several laboratory and clinical parameters including tVPA, albumin, age, sex, congestive heart failure, obesity, and diabetes mellitus were chosen in the final model. In all patients, our equation demonstrated a concordance rate of 66.3% and a bias of 1.46% between the estimated fVPA and the measured fVPA. Likewise, our equation displayed a concordance rate of 70.0% and a bias of -0.03% for patients with normal albumin levels. For patients with hypoalbuminemia, the concordance rate was 69.5% with a bias of 1.97%. In comparison to three previously published equations, our equations obtained increased concordance and decreased bias between estimated fVPA and measured fVPA.ConclusionsOur data indicate that free VPA and total VPA do not correlate well according to the therapeutic ranges, especially in patients with hypoalbuminemia. Compared with previously reported equations, our equations showed enhanced concordance and reduced bias between estimated fVPA and measured fVPA, in both patients with normal albumin levels and patients with hypoalbuminemia. Further validation is needed to evaluate the accuracy and generalizability of the equations before clinical application.

Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia

Population Pharmacokinetics of Valproate in Chinese Children with Epilepsy.

Population Pharmacokinetics of Valproate in Children with Epilepsy by NONMEM

Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen

Establishment of Population Phamacokinetic Model of Valproic Acid in Chinese Epileptic Children

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim

Establishment of Population Pharmacokinetic Models with Valproic Acid in Different Age Groups of Chinese Epileptic Children

Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs

Setting up population pharmacokinetics/pharmacodynamics model of VPA in children with epilepsy by NONMEM software

Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained‐release tablets

Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents

Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis

A randomized controlled trial of initial Valproic acid dosage in epileptic children

B-304 Development of free valproic acid estimating equations for adult epileptic patients

Effects of Valproic Acid on Organic Acid Metabolism in Children: A Metabolic Profiling Study

Developing pharmacokinetics–pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

Physiologically based pharmacokinetic models for predicting lamotrigine exposure and dose optimization in pediatric patients receiving combination therapy with carbamazepine or valproic acid

Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients with Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy

Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates

A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations